Nicole Kabella

This study uses pan-cancer phosphoproteomics to identify therapeutic targets and improve precision oncology by analyzing 1,998 tumor samples and developing new scores for kinase activity and immune response.

The paper develops a method to identify and validate kinase-substrate relationships using phosphoproteomics data and applies it to estimate kinase activity in cancer biopsies.

The paper uses chemical proteomics to analyze KRAS inhibitor effects on signaling networks in cancer cells, revealing cell-specific responses and phosphorylation changes.

The paper evaluates proteome analysis performance across different chromatographic flow rates and shows that all are suitable for high-quality analysis, with capLC being a robust alternative to nanoLC.